E-16 | Age, Sex and Pacemakers: Medtronic CoreValve vs. Edwards Sapien Valve Use in the Real World

Transcatheter aortic valve replacement (TAVR) has emerged as a viable alternative to surgical aortic valve replacement, especially in high-risk patients. We assessed the in-hospital outcomes of the two most widely used TAVR valves in a contemporary database, the self-expanding Medtronic CoreValve and the balloon expandable Edwards Sapien. Data was collected on all pts that underwent TAVR between 2021-2022 at 4 New York metropolitan area hospitals and entered to the STS ACC TAVR registry for quality assurance. Outcomes were classified according to the Valve Academic Research Consortium (VARC-3) criteria. A Total of 1,510 patients underwent TAVR, 922 Edwards Sapien valve and 588 Medtronic CoreValve (Table). Patients treated with the Medtronic valve were older and usually female. In-hospital vascular and bleeding complications were similar in both groups. There was a higher rate of ischemic stroke and need for permanent pacemaker implant in the Medtronic CoreValve group. As in previous studies, the Medtronic CoreValve was more frequently used in female patients and was associated with a greater need for permanent pacemaker implantation and stroke. Not clear if the higher rate of ischemic stroke was related to post-implant valve dilatation. Future research should focus on the impact of patient-specific factors on valve choice and performance.